Cytek owes Beckman Coulter $56 mln in cell-analysis patent case, US jury says
CTKB•Cytek revenue context
California-based Cytek earned $201.5 million from overall sales of its products last year, according to a company report.
Damages award totals $56 million
The jury said that Cytek owed Beckman $36 million in royalties and $20 million in lost profits.
Spokespeople for the companies did not immediately respond to requests for comment on the verdict.
Earlier patent rulings in the case
Beckman first sued Cytek over the patents in 2024.
Cytek denied the allegations and argued the patents were invalid.
The jury found on Thursday that Cytek did not infringe two of the three patents at issue in the trial and that those two patents were invalid.
Jury finds Cytek infringed Beckman patent
A Delaware federal jury determined on Friday that Cytek Biosciences' products for analyzing single-cell blood and tissue samples infringe a patent owned by rival Beckman Coulter.
The jury agreed with Danaher-owned Beckman that Cytek's Aurora flow cytometers and other products violate Beckman's patent rights in technology used in its competing CytoFLEX platform.
